Albert D. Friesen
Albert D. Friesen | |
|---|---|
.jpg) | |
| Born | May 19, 1947 |
| Occupation(s) | President and CEO |
| Employer | Winnipeg Rh Institute |
| Known for | WinRho |
Albert "Bert" D. Friesen, OM (born May 19, 1947) is a Canadian biotechnologist involved in biotechnology innovation.[1] His biotechnology career began as the first full-time employee of the Winnipeg Rh Institute, where he later became president and CEO, and led the development of WinRho, one of Canada's first successful biotech products.[2]
Education
[edit]Albert Friesen went to the University of Manitoba and earned a Ph.D. in protein chemistry.[3]
Career
[edit]In 1987, Dr. Friesen was a founder and the company’s first board of directors Chairman at the Industrial Biotechnology Association of Canada (IBAC) which is now known as BIOTECanada.[4]
In 1997, Friesen founded Medicure, which sells a large number of cardiovascular products. In 2020, Medicure purchased Marley Drug and the company can now sell medications directly to patients.[4]
From 2014-2017, Friesen was chair on the International board of MEDA (Mennonite Economic Development Associates).[4]
In March 2023, Dr. Friesen was awarded Outstanding Leadership in Bioscience of the Year at the Annual Bioscience Association Manitoba (BAM) gala.[4]
References
[edit]- ^ "Local bio-entrepreneur to be honoured". Winnipeg Free Press. 2013-04-22. Retrieved 2016-07-20.
- ^ "Manitoba's Bio Builder - Biotechnology FocusBiotechnology Focus | Biotechnology Focus – Leading change in Canada's life science industry, from innovation to business". Biotechnologyfocus.ca. 2013-09-06. Retrieved 2016-07-20.
- ^ "Albert Friesen". MEDA. Retrieved 2024-11-27.
- ^ a b c d "Albert Friesen | BAM Outstanding Leadership in Bioscience". Medicure Inc. Retrieved 2024-11-15.
.svg){kind=small}   | This article about a Canadian scientist is a stub. You can help Wikipedia by expanding it. |
 | This biotechnology article is a stub. You can help Wikipedia by expanding it. |